トール様受容体3(CD283またはTLR3)パイプライン標的は約12の分子で構成されています。そのうち約10分子が企業によって開発され、残りは大学や研究機関によって開発されています。本レポートは、トール様受容体3を標的とした治療薬に関する包括的な情報を、適応症、開発段階、作用機序(MoA)、投与経路(RoA)、分子タイプ別に分析します。
トール様受容体3は、TLR3遺伝子によってコードされるタンパク質です。微生物に特異的な分子パターンを認識することで、病原体に対する宿主の免疫反応を制御します。TLR3は、ウイルス感染のサインである二本鎖RNAによって活性化されるヌクレオチド感知型のTLRです。アダプターのTRIF/TICAM1を介して作用し、NF-カッパ-Bの活性化、IRF3の核内移行、サイトカインの分泌、炎症反応を引き起こします。申請却下/取り消し、フェーズII、フェーズI、前臨床、および創薬段階の企業によって開発された分子は、それぞれ1、3、2、2、および2分子です。 同様に、前臨床段階の大学ポートフォリオは、2つの分子で構成されています。
本レポートは、腫瘍学、感染症、胃腸、免疫学、中枢神経系、および呼吸器の治療領域からの製品をカバーしています。新型コロナウイルス感染症(COVID-19)、メラノーマ、膀胱癌、乳癌、上皮性卵巣癌、ヒト免疫不全ウイルス(HIV)感染症(AIDS)、転移性結腸直腸癌、腹膜癌、重症急性呼吸器症候群(SARS)、急性炎症、慢性疲労症候群(筋痛性脳脊髄炎)、慢性炎症、結腸癌、結腸直腸癌、皮膚T細胞リンパ腫、サイトメガロウイルス(HHV-5)感染症、エボラウイルス感染症(エボラ出血熱)、ファロピウス管癌、胃癌、胃食道(GE)接合部癌、頭頸部癌、頭頸部癌扁平上皮細胞癌、B型肝炎、肝細胞癌、口唇ヘルペス、炎症、インフルエンザAウイルス、H3N2サブタイプ感染症、インフルエンザAウイルス、H5N1サブタイプ感染症、インフルエンザAウイルス、H 7N9サブタイプ感染症、腎臓癌(腎細胞癌)、悪性胸膜中皮腫、メルケル細胞癌、膵臓の転移性腺癌、転移性黒色腫、非筋肉浸潤性膀胱癌(NMIBC)(表在性膀胱癌)、非小細胞肺癌、卵巣癌、膵臓癌、膵管腺癌、汎発性インフルエンザ、前立腺癌、肺炎症、腎細胞癌、ライノウイルス感染症、肉腫、トリプルネガティブ乳癌(TNBC)、潰瘍性大腸炎、不特定インフルエンザウイルス感染症、西ナイルウイルス感染症、ジカウイルス感染症などが含まれます。
また、トール様受容体3を標的とした治療薬開発に関わる主要企業と、それぞれの活動中、休止中、中止のプロジェクトについてもレビューしています。本レポートは、独自のデータベース、企業/大学のウェブサイト、臨床試験登録、カンファレンス、SECファイリング、投資家向けプレゼンテーション、企業/大学のサイトや業界特有の第三者の情報源から得られた注目のプレスリリースなどから得られたデータや情報を基にして作成されています。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 3 (CD283 or TLR3) - Overview
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development
13therapeutics Inc
AIM ImmunoTech Inc
Glysantis Inc
HDT Bio Corp
Highlight Therapeutics SL
Oncovir Inc
PrEP Biopharm Ltd
Provention Bio Inc
Tollys SAS
Yisheng Biopharma Co Ltd
Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles
Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BO-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLY-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Agonize TLR3 for Head and Neck Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Poly-ICLC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PrEP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRV-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TL-532 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YSHBV-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products
Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products
Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones
Featured News & Press Releases
Mar 22, 2021: AIM ImmunoTech announces addition of single-agent Ampligen arm to Cancer Center’s ongoing study in cancer patients with COVID-19
Mar 09, 2021: AIM ImmunoTech initiates dosing in intranasal Covid-19 drug study
Mar 02, 2021: Highlight & Pivotal start Phase IIa melanoma trial
Feb 24, 2021: AIM ImmunoTech’s subsidiary receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to treat pancreatic cancer
Feb 17, 2021: AIM ImmunoTech to commence study of intranasal Covid-19 therapy
Feb 17, 2021: AIM ImmunoTech to commence study of intranasal Covid-19 therapy
Feb 10, 2021: AIM ImmunoTech announces the expansion of its pancreatic cancer program to include new patients in the Netherlands
Jan 29, 2021: AIM ImmunoTech enters into agreement for proposed intranasal safety study of ampligen
Jan 07, 2021: AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection
Dec 24, 2020: AIM ImmunoTech announces availability of the ME/CFS clinical trial of its drug Ampligen for enrollment to COVID-19 ‘Long Haulers’
Dec 23, 2020: Open Orphan: Successful completion of PrEP Biopharm Toxicology study for respiratory 'viral mimic'
Dec 21, 2020: AIM ImmunoTech's drug Ampligen awarded FDA’s Orphan Drug Designation status for the treatment of pancreatic cancer
Dec 16, 2020: PrEP Biopharm announces successful completion of PrEP-001 toxicology study enabling phase 2b field study of PrEP-001 against all respiratory viruses
Nov 25, 2020: AIM announces milestone in covid-19 treatment and prevention efforts with first patient dosed in study evaluating Ampligen as part of combination treatment for patients with cancer and covid-19
Nov 02, 2020: AIM ImmunoTech announces PLOS ONE’s publication of new data analyses showing importance of disease duration on Ampligen’s positive role in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by 13therapeutics Inc, 2021
Pipeline by AIM ImmunoTech Inc, 2021
Pipeline by Glysantis Inc, 2021
Pipeline by HDT Bio Corp, 2021
Pipeline by Highlight Therapeutics SL, 2021
Pipeline by Oncovir Inc, 2021
Pipeline by PrEP Biopharm Ltd, 2021
Pipeline by Provention Bio Inc, 2021
Pipeline by Tollys SAS, 2021
Pipeline by Yisheng Biopharma Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021
List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021